Summary:
In patients with type 2 diabetes, personalized exercise prescriptions based on the Chester Step Test (CST) significantly reduced postprandial glucose levels and glycemic variability compared to a non-exercise control group, though it was associated with no notable adverse events.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetes (T2D), recruited from outpatient settings between April 2022 and August 2024. |
| Intervention | Personalized exercise program prescribed based on Chester Step Test-derived VO2 max, performed 45 minutes after dinner at 50%–75% of VO2 max intensity for 30–60 minutes per session. |
| Comparison | Control group continuing usual routine activities without participation in vigorous physical activity. |
| Outcome | On exercise days, the intervention group demonstrated significantly lower postprandial nadir glucose (4.5 ± 1.15 mmol/L vs 5.4 ± 0.98 mmol/L, P = .0160), reduced blood glucose standard deviation (1.5 ± 0.41 mmol/L vs 2 ± 0.36 mmol/L, P = .0272), and decreased mean amplitude of glycemic excursions (3.6 ± 1.86 mmol/L vs 5.5 ± 1.82 mmol/L, P = .0094) compared to controls. No significant adverse effects were reported. |
Source: Chen Wang, et al. “Clinical application of Chester Step Test in developing personalized exercise prescription in patients with type 2 diabetes: A single-blind, randomized controlled trial.” Read article here.
